ECSP10010384A - Nuevas piridinonas y piridazinonas - Google Patents
Nuevas piridinonas y piridazinonasInfo
- Publication number
- ECSP10010384A ECSP10010384A EC2010010384A ECSP10010384A ECSP10010384A EC SP10010384 A ECSP10010384 A EC SP10010384A EC 2010010384 A EC2010010384 A EC 2010010384A EC SP10010384 A ECSP10010384 A EC SP10010384A EC SP10010384 A ECSP10010384 A EC SP10010384A
- Authority
- EC
- Ecuador
- Prior art keywords
- iii
- btk
- compounds
- phenyl
- useful
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- IJUIPRDMWWBTTQ-UHFFFAOYSA-N 3-phenyl-1h-pyridazin-6-one Chemical class N1C(=O)C=CC(C=2C=CC=CC=2)=N1 IJUIPRDMWWBTTQ-UHFFFAOYSA-N 0.000 abstract 1
- RWFAQYWIBBVEBY-UHFFFAOYSA-N 5-phenyl-1h-pyridin-2-one Chemical compound N1C(=O)C=CC(C=2C=CC=CC=2)=C1 RWFAQYWIBBVEBY-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Esta solicitud se refiere a derivados de 5-fenil-1H-piridin-2-ona y 6-fenil-2H-piridazin-3-ona de las fórmulas genéricas I-III: (I) (II) (III)en las que las variables R, X, Y1, Y2, Y3, Y4, n y m tienen los significados definidos anteriormente, que inhiben la Btk. Los compuestos aquí descritos son útiles para modular la actividad de la Btk y tratar enfermedades asociadas con una actividad excesiva de la Btk. Además, estos compuestos son útiles para tratar enfermedades inflamatorias y autoinmunes asociadas con la proliferación aberrante de células B, por ejemplo la artritis reumatoide. Se describen también composiciones que contienen los compuestos de las fórmulas I-III y por lo menos un vehículo, diluyente o excipiente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2620408P | 2008-02-05 | 2008-02-05 | |
| US12251008P | 2008-12-15 | 2008-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010384A true ECSP10010384A (es) | 2010-09-30 |
Family
ID=40413736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010384A ECSP10010384A (es) | 2008-02-05 | 2010-08-05 | Nuevas piridinonas y piridazinonas |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP2242749B1 (es) |
| JP (1) | JP5259739B2 (es) |
| KR (1) | KR101308803B1 (es) |
| CN (1) | CN101932573B (es) |
| AR (1) | AR070408A1 (es) |
| AU (1) | AU2009211514B2 (es) |
| BR (1) | BRPI0907915A2 (es) |
| CA (1) | CA2710462C (es) |
| CL (1) | CL2009000229A1 (es) |
| CO (1) | CO6290767A2 (es) |
| CR (1) | CR11598A (es) |
| CY (1) | CY1114114T1 (es) |
| DK (1) | DK2242749T3 (es) |
| EC (1) | ECSP10010384A (es) |
| ES (1) | ES2420846T3 (es) |
| HR (1) | HRP20130615T1 (es) |
| IL (1) | IL206357A (es) |
| MA (1) | MA32064B1 (es) |
| MX (1) | MX2010008197A (es) |
| MY (1) | MY158411A (es) |
| NZ (1) | NZ586916A (es) |
| PE (1) | PE20091484A1 (es) |
| PL (1) | PL2242749T3 (es) |
| PT (1) | PT2242749E (es) |
| RU (1) | RU2505538C2 (es) |
| SI (1) | SI2242749T1 (es) |
| TW (1) | TWI382024B (es) |
| WO (1) | WO2009098144A1 (es) |
| ZA (1) | ZA201005539B (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012502374A1 (en) | 2008-06-24 | 2014-11-12 | Hoffmann La Roche | Novel substituted pyridin-2-ones and pyridazin-3-ones |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| WO2010122038A1 (en) * | 2009-04-24 | 2010-10-28 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| NZ598985A (en) | 2009-09-04 | 2013-07-26 | Biogen Idec Inc | Bruton's tyrosine kinase inhibitors |
| EP2566869B1 (en) * | 2010-05-07 | 2016-03-02 | Gilead Connecticut, Inc. | Pyridone and aza-pyridone compounds and methods of use |
| EP2394998A1 (en) * | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| AU2012257802A1 (en) * | 2011-05-17 | 2013-10-31 | F. Hoffmann-La Roche Ag | Inhibitors of Bruton's tyrosine kinase |
| CA2841801A1 (en) * | 2011-08-17 | 2013-02-21 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| US9365566B2 (en) | 2012-03-27 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives |
| KR20150000882A (ko) | 2012-04-05 | 2015-01-05 | 씨에이치디아이 파운데이션, 인코포레이티드 | 키뉴레닌-3-모노산소첨가효소 억제제들, 약학 조성물들 및 이의 사용 방법 |
| JP6182593B2 (ja) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| WO2014040965A1 (en) * | 2012-09-13 | 2014-03-20 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| JP6088063B2 (ja) * | 2012-11-16 | 2017-03-01 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトン型チロシンキナーゼの阻害剤 |
| MX2015006457A (es) * | 2012-11-30 | 2015-08-14 | Hoffmann La Roche | Inhibidores de la tirosina cinasa de bruton. |
| RU2618529C2 (ru) * | 2013-03-05 | 2017-05-04 | Ф. Хоффманн-Ля Рош Аг | Ингибиторы тирозинкиназы брутона |
| EP2964642B1 (en) * | 2013-03-05 | 2017-11-15 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
| CN104177338B (zh) * | 2013-05-22 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类布鲁顿激酶抑制剂 |
| WO2015000949A1 (en) * | 2013-07-03 | 2015-01-08 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone amide compounds |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| WO2015082583A1 (en) * | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| CN106922146B (zh) * | 2014-10-02 | 2020-05-26 | 豪夫迈·罗氏有限公司 | 用于治疗由布鲁顿酪氨酸激酶(btk)介导的疾病的吡唑甲酰胺化合物 |
| US10570118B2 (en) * | 2016-01-13 | 2020-02-25 | Boehringer Ingelheim International Gmbh | Isoquinolones as BTK inhibitors |
| DK3436447T3 (da) | 2016-03-31 | 2021-09-13 | Takeda Pharmaceuticals Co | Isoquinolinyl-triazolon-komplekser |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| JP7214632B2 (ja) | 2016-07-21 | 2023-01-30 | バイオジェン エムエー インク． | ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物 |
| WO2018033853A2 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| WO2018033135A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
| IL292938A (en) | 2016-09-19 | 2022-07-01 | Mei Pharma Inc | Combined treatment |
| US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| CN106967073A (zh) * | 2017-04-24 | 2017-07-21 | 刘双伟 | 一种治疗类风湿性关节炎的药物 |
| CN106946891B (zh) * | 2017-05-08 | 2018-07-13 | 宿州市徽腾知识产权咨询有限公司 | 一种用于治疗类风湿性关节炎的药物 |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| MX2021004191A (es) | 2018-10-15 | 2021-05-27 | Nurix Therapeutics Inc | Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma. |
| US12582722B2 (en) | 2019-02-13 | 2026-03-24 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CA3136348A1 (en) | 2019-04-09 | 2020-10-15 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus |
| AU2020278592B2 (en) | 2019-05-17 | 2024-10-10 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof |
| US20220249491A1 (en) | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
| MX2021015675A (es) | 2019-06-26 | 2022-02-03 | Nurix Therapeutics Inc | Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos. |
| EP4034140A1 (en) | 2019-09-24 | 2022-08-03 | Nurix Therapeutics, Inc. | Cbl inhibitors and compositions for use in adoptive cell therapy |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| US20230024442A1 (en) * | 2019-11-08 | 2023-01-26 | Nurix Therapeutics, Inc. | Bifunctional compounds for grading btk via ubiquitin proteosome pathway |
| WO2021113557A1 (en) | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022217123A2 (en) | 2021-04-08 | 2022-10-13 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds |
| CA3236073A1 (en) | 2021-10-26 | 2023-05-04 | Robert J. Brown | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3951395B2 (ja) * | 1996-12-13 | 2007-08-01 | 田辺製薬株式会社 | ピリジン誘導体、その製法及びその合成中間体 |
| ATE278674T1 (de) * | 1999-03-12 | 2004-10-15 | Boehringer Ingelheim Pharma | Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel |
| ES2232306B1 (es) * | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| US8101770B2 (en) * | 2004-12-16 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
| MY140868A (en) * | 2004-12-24 | 2010-01-29 | Astrazeneca Ab | Amide derivatives |
| MX2007011041A (es) * | 2005-03-10 | 2008-02-22 | Cgi Pharmaceuticals Inc | Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas. |
| WO2006124731A2 (en) * | 2005-05-12 | 2006-11-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2007021795A2 (en) * | 2005-08-09 | 2007-02-22 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| ATE548363T1 (de) * | 2005-08-29 | 2012-03-15 | Vertex Pharma | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen |
| MX2008014618A (es) * | 2006-05-15 | 2008-11-28 | Irm Llc | Composiciones y metodos para inhibidores de cinasas del receptor fgf. |
-
2009
- 2009-01-27 PL PL09709135T patent/PL2242749T3/pl unknown
- 2009-01-27 KR KR1020107016014A patent/KR101308803B1/ko not_active Expired - Fee Related
- 2009-01-27 WO PCT/EP2009/050875 patent/WO2009098144A1/en not_active Ceased
- 2009-01-27 CA CA2710462A patent/CA2710462C/en not_active Expired - Fee Related
- 2009-01-27 HR HRP20130615AT patent/HRP20130615T1/hr unknown
- 2009-01-27 CN CN200980103857.3A patent/CN101932573B/zh not_active Expired - Fee Related
- 2009-01-27 MY MYPI2010003693A patent/MY158411A/en unknown
- 2009-01-27 BR BRPI0907915-7A patent/BRPI0907915A2/pt not_active IP Right Cessation
- 2009-01-27 NZ NZ586916A patent/NZ586916A/en not_active IP Right Cessation
- 2009-01-27 PT PT97091359T patent/PT2242749E/pt unknown
- 2009-01-27 JP JP2010545433A patent/JP5259739B2/ja not_active Expired - Fee Related
- 2009-01-27 EP EP09709135.9A patent/EP2242749B1/en not_active Not-in-force
- 2009-01-27 SI SI200930630T patent/SI2242749T1/sl unknown
- 2009-01-27 DK DK09709135.9T patent/DK2242749T3/da active
- 2009-01-27 ES ES09709135T patent/ES2420846T3/es active Active
- 2009-01-27 RU RU2010136665/04A patent/RU2505538C2/ru not_active IP Right Cessation
- 2009-01-27 MX MX2010008197A patent/MX2010008197A/es active IP Right Grant
- 2009-01-27 AU AU2009211514A patent/AU2009211514B2/en not_active Expired - Fee Related
- 2009-02-03 CL CL2009000229A patent/CL2009000229A1/es unknown
- 2009-02-03 TW TW098103399A patent/TWI382024B/zh not_active IP Right Cessation
- 2009-02-03 AR ARP090100345A patent/AR070408A1/es not_active Application Discontinuation
- 2009-02-04 PE PE2009000169A patent/PE20091484A1/es not_active Application Discontinuation
-
2010
- 2010-06-14 IL IL206357A patent/IL206357A/en not_active IP Right Cessation
- 2010-07-26 CO CO10090865A patent/CO6290767A2/es active IP Right Grant
- 2010-07-27 CR CR11598A patent/CR11598A/es not_active Application Discontinuation
- 2010-08-03 ZA ZA2010/05539A patent/ZA201005539B/en unknown
- 2010-08-05 EC EC2010010384A patent/ECSP10010384A/es unknown
- 2010-08-06 MA MA33066A patent/MA32064B1/fr unknown
-
2013
- 2013-07-08 CY CY20131100576T patent/CY1114114T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010384A (es) | Nuevas piridinonas y piridazinonas | |
| ECSP10010709A (es) | Nuevas piridin-2-onas y piridazin-3-onas sustituidas | |
| ECSP13012437A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| ECSP13013025A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| ECSP14013212A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| PE20151336A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| CL2011002726A1 (es) | Compuestos derivados de sulfonamidas, sus n-oxidos y sus sales; composicion que los comprende; metodo para controlar un nematodo parasitico y semilla tratada. | |
| UY29458A1 (es) | Heterociclos sustituidos y usos de los mismos | |
| CO2025000537A2 (es) | Compuestos heteroarílicos como degradadores de irak4 dirigidos por el ligando | |
| ECSP11011183A (es) | Compuestos orgánicos | |
| NI200900190A (es) | Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal. pc33495a | |
| GT200800158A (es) | Pirazolquinolonas como potentes inhibidores de parp | |
| CY1114223T1 (el) | Πρωτοτυπες φαινυλοπυραζινονες ως αναστολεις κινασης | |
| CL2010001637A1 (es) | Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras. | |
| CR20110614A (es) | Compuestos de triazol que portan un sustituyente de azufre x | |
| ECSP088527A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| DOP2006000032A (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a | |
| BR112014013582A8 (pt) | inibidores de quinase de tirosina de bruton | |
| DOP2008000089A (es) | 18-metil-19-nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen | |
| ECSP10010705A (es) | Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa | |
| UY31750A (es) | Compuestos y composiciones como inhibidores de quinasa | |
| CR11636A (es) | Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos | |
| NI200900147A (es) | Nuevos derivados tricíclicos su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| UY29613A1 (es) | Compuestos quimicos vi | |
| CO6341477A2 (es) | Compuestos pirrolopirimidincarboxamida, procesos para su producción y composiciones farmaceúticas que comprenden dichos compuestos |